CAR T Cell Therapy

Promising technologies for lymphoma, leukemia & multiple myeloma treatment.

Chimeric Antigen Receptor T-cell therapy is also known as CAR T cell therapy, it is a recently developed cancer treatment that offers hope to people with lymphoma, leukemia and multiple myeloma that are hard to treat. lt has the potential to cure cancer and was approved by the FDA in the US in 2017.

China is among the first countries to offer CAR T cell therapies, since 2021, the treatment has been approved by the National Medical Products Administration (NMPA) of China in the treatment of lymphoma, leukemia and multiple myeloma. Hundreds of patients have been treated with this revolutionary therapy in hospitals in China.

The research and development of CAR T cell therapy in China is rapid, and the doctors are experienced in handling CAR T cell therapy. China has surpassed the US and became the first in terms of the number of clinical trials, there are over 500 trials taking place at present in the country, the overall cure rate of CAR T cell therapy in China is among the best in the world.

Apart from the doctors’ expertise, China offers medical care at an affordable cost, including CAR T cell therapy. CAR T cell therapy is a pricey treatment, it costs USD 450,000 in the US, however, it costs less than half in China, and most importantly, there is no deduction in quality.

Here, we will go through the process you will undergo if you are potentially qualified for the treatment. If you are interested in traveling to China and receiving CAR T cell therapy feel free to contact us using the contact form on the right, we will contact you shortly with detailed information, and will help you go through the process of traveling over to China.

Why going to China for cancer treatment?

Fact of CAR T Cell Therapy in China

0
Approved Therapies
0 %
Remission Rate
0 +
Patients Treated
0 +
Clinical Studies

Potential Benefits

CAR T-cell therapy is a form of immunotherapy thatuses engineered T cells to fight against cancer.These T cells are part of our immune responsible tokill “foreign” objects, such as cancer, in our body byrecognizing special protein presented (CD19) on thesurface of the cancer cells. These T cells aremodified in the lab and are stimulated with antigen CD19, so that they can find and destroy the cancercells after being infused back to patient’s body.Previous studies indicated encouraging outcomes in non-Hodgkin lymphoma.

At present, CAR T-cell therapies have beenapproved in the treatment of relapsed andrefractory non-Hodgkin lymphoma, CAR T-celltherapy is recommended for patients with the following diagnosis:

  • Diffuse large B-cell lymphoma (DLBCL)
  • Primary diastinal B-cell lymphoma (PMBCL)
  • LBCL transformed from high-grade B-cell lymphoma
  • Follicular lymphoma

Effectiveness of CAR T Cell Therapy

CAR T cell therapy has shown promising outcomes in the treatment of lymphoma, many patients who had previously relapsed lymphoma experienced positive outcomes and no evidence of recurrence of cancer.

According to Gilead, Yescarta demonstrates 78% Complete Response Rate asPart of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma. After a single infusion of Yescarta, 89% of evaluable patients achieved a response (ORR)(n=37 evaluable for efficacy), including 78% of patients with a complete response (CR) at a median follow-up of 15.9 months.

Gilead has also presented four-year survival data for Yescarta in the ZUMA-1 study of patients with refractory large B-cell lymphoma. Based on these dat aand other data presented at ASH, Kite believes that Yescarta could bring the hope of survival to patients with a number of other hematological malignancies. However, longer-term studies for a larger patient population are needed to validate the efficacy of this treatment. Large-scale experiments would also aid in determining the likelihood of side effects and the right ways to deal with them.

Development of CAR T-Cell therapy in China

According to data published on ClinicalTrials.gov, among 25 countries that have initiated clinical trials with CAR T-cells, China is the country with the majority of CAR T cell clinical trials registered as of March 2022, with 460 studies, followed by the USA presented 286 studies, while the Uk had 14, and Germany had 9.
Furthermore, CDl9 is the most frequently examined target in these registered clinical studies. CD20, CD22, and BCMA are also common CAR T cell therapy targets for hematologic malignancies. Research of CAR T-cell therapy in the treatment of solid cancers are undergo in a number of institutes.

Treatment Process

Unlike other treatments such as chemotherapy or radiotherapy, CAR T-cell therapy is a biological and personalized live medicine manufactured from patient’s own white blood cells, its criteria and requirement must be followed in order for a safe and effective treatment. Here are a few steps a patient will go through if he wishes to have CAR T cell therapy.

1. Evaluation

A full assessment of patient's condition is performedbefore CAR T-cell therapy.

2.WBC Collection

Collecting patient's own white blood cells formanufacture of CAR T-cells.

3.T Cell Modification & Growth

T cells are engineered and multiplied in the lab to recognize cancer cells in patient's body.

4.Pre-treatment

Chemotherapy may be required prior to CAR T cell therapy for better effort.

5.Infusion of CAR T Cells

Infusing CAR T cells back to patient's body, and fightagainst cancer.

6.Recovery

A 2-3 month of recovery period is needed after treatment.

Side Effects

The side effects of CAR T-cell therapy usually resolve on their own or they can be managed with medications.The common side effects ofCAR T-cell therapy include.

Cytokine release syndrome

In some cases, patients may develop flu-like symptoms such as fever, chills, headache, nausea, vomiting, loose stools, and muscle or joint pains. it may also cause low blood pressure, dificulty in breathing, and a fast heart rate. these side effects are due to the release of cytokines by the immune cells during CAR T cell therapy. These symptoms are usualy mild, but can be serious and life threatening in some patients.

Neurological events

Neurological events can occur and can be serious in some patients. such events include encephalopathy (brain iniury and malfunction confusion, difficulty speaking, agitation, seizures, drowsiness, altered state of consciousness and loss of balance.

Neutropaenia and Anaemid

Some patients may develop neutropenia or low white cell count. similarly,anaemia or low red blood cell count may also occur due to this therapy.